SGMOQ Sangamo Therapeutics (SGMOQ) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001001233
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter
Sangamo Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SANGAMO THERAPEUTICS, INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
below 99% of Pharma & Biotech
Revenue
-31.6% year over year
below 72% of Pharma & Biotech
Margin
-310.8% net margin
below 72% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.6% of the float short (float per yahoo 2026-10-26) · 3.3 days to cover · settled 2026-09-30
below 64% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SGMOQ
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns SGMOQ: institutional holders (13F)
13F holdings, latest reported quarter
$22.0K
76,500 sh
$4.1K
25,375 sh
$1.4K
10,000 sh
$539
21,532 sh
$1
Congress trades in SGMOQ
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SGMOQ planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SGMOQ mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Nomura Healthcare Fund
$21.6K position · as of 2026-06-30
0.0%
VIP Disciplined Small Cap Portfolio
$11.9K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
5
Not applicable
3 active
6
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Alexander D. Macrae
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$2.5M
$4.0M
$1.2M
-86%
n/a
2023
$2.4M
-$340.2K
$1.0M
-93%
n/a
2022
$4.8M
$967.9K
$1.5M
-58%
n/a
2021
$4.7M
-$1.6M
$1.3M
-10%
+26%
2020
$3.8M
$9.6M
$1.7M
+86%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 3 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SGMOQ financials
Revenue growth
-31.6%
XBRL, annual
Net margin
-310.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$34.6M
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM SGMOQ
| FY Dec 2025 | $39.6M |
| FY Dec 2024 | $57.8M |
| FY Dec 2023 | $176.2M |
| FY Dec 2022 | $111.3M |
| FY Dec 2021 | $110.7M |
| Mar 2026 | $1.4M |
| Dec 2025 | $14.2M |
| Sep 2025 | $581.0K |
| Jun 2025 | $18.3M |
| Mar 2025 | $6.4M |
| Dec 2024 | $7.6M |
| Sep 2024 | $49.4M |
| Jun 2024 | $356.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-356.9%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM SGMOQ
| FY Dec 2025 | -310.8% |
| FY Dec 2024 | -169.4% |
| FY Dec 2023 | -146.3% |
| FY Dec 2022 | -172.8% |
| FY Dec 2021 | -161.1% |
| Mar 2026 | -2,149% |
| Dec 2025 | -263.0% |
| Sep 2025 | -6,012% |
| Jun 2025 | -109.2% |
| Mar 2025 | -475.3% |
| Dec 2024 | -309.8% |
| Sep 2024 | +21.6% |
| Jun 2024 | -10,148% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$90.5M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM SGMOQ
| FY Dec 2025 | -$97.3M |
| FY Dec 2024 | -$67.4M |
| FY Dec 2023 | -$246.0M |
| FY Dec 2022 | -$243.8M |
| FY Dec 2021 | -$256.5M |
| Mar 2026 | -$19.3M |
| Dec 2025 | -$24.4M |
| Sep 2025 | -$28.6M |
| Jun 2025 | -$18.2M |
| Mar 2025 | -$26.1M |
| Dec 2024 | -$3.5M |
| Sep 2024 | $11.6M |
| Jun 2024 | -$26.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity SGMOQ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt SGMOQ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity SGMOQ
| FY Dec 2025 | -2,892% |
| FY Dec 2024 | -185.4% |
| FY Dec 2023 | -136.5% |
| FY Dec 2022 | -57.4% |
| FY Dec 2021 | -40.8% |
| Mar 2026 | n/a |
| Dec 2025 | -2,892% |
| Sep 2025 | -480.0% |
| Jun 2025 | -292.5% |
| Mar 2025 | -257.9% |
| Dec 2024 | -185.4% |
| Sep 2024 | -154.9% |
| Jun 2024 | -194.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-168.8%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets SGMOQ
| FY Dec 2025 | -152.4% |
| FY Dec 2024 | -73.4% |
| FY Dec 2023 | -70.8% |
| FY Dec 2022 | -29.9% |
| FY Dec 2021 | -21.5% |
| Mar 2026 | -168.8% |
| Dec 2025 | -152.4% |
| Sep 2025 | -109.0% |
| Jun 2025 | -66.4% |
| Mar 2025 | -73.9% |
| Dec 2024 | -73.4% |
| Sep 2024 | -81.5% |
| Jun 2024 | -119.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SGMOQ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-568.9%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed SGMOQ
| FY Dec 2025 | -331.7% |
| FY Dec 2024 | -119.9% |
| FY Dec 2023 | -96.4% |
| FY Dec 2022 | -38.5% |
| FY Dec 2021 | -26.4% |
| Mar 2026 | -568.9% |
| Dec 2025 | -331.7% |
| Sep 2025 | -204.5% |
| Jun 2025 | -121.0% |
| Mar 2025 | -131.0% |
| Dec 2024 | -119.9% |
| Sep 2024 | -117.0% |
| Jun 2024 | -158.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
no close on file at or before the as-of date
P/E, trailing SGMOQ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no close on file at or before the as-of date
Enterprise value SGMOQ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no close on file at or before the as-of date
FCF yield SGMOQ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
no close on file at or before the as-of date
PEG, trailing SGMOQ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $39.6M | $57.8M | $176.2M | $111.3M |
| Operating income | -$121.2M | -$104.0M | -$274.0M | -$201.3M |
| Net income | -$122.9M | -$97.9M | -$257.8M | -$192.3M |
| EPS (diluted) | -0.44 | -0.49 | -1.48 | -1.25 |
| Operating cash flow | -$97.2M | -$67.1M | -$224.8M | -$223.6M |
| Cash | $20.9M | $41.9M | $45.2M | $100.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
SGMOQ Stock Sonar score 4/7 axes
Find similar shapesCompareSGMOQ ranks highest on risk and compliance (49th percentile) and growth (28th), and lowest on institutional and government (1st), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
